Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Versus Cetuximab as Maintenance Therapy in First-Line Therapy for RAS and BRAF Wild-Type Metastatic Colorectal Cancer: Phase III ERMES Study.
Carmine PintoArmando OrlandiNicola NormannoEvaristo MaielloMaria Alessandra CalegariLorenzo AntonuzzoRoberto BordonaroMaria G ZampinoSara PiniFrancesca BergamoGiuseppe ToniniAntonio AvalloneTiziana P LatianoGerardo RosatiAlessio Aligi CogoniAlberto BallestreroAlberto ZaniboniMario RoselliStefano TamberiCarlo BaronePublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
The ERMES study did not demonstrate noninferiority of maintenance with Cet alone. Despite a more favorable safety profile, maintenance with single-agent Cet after induction with FOLFIRI/Cet cannot be recommended for all patients but could represent an option in selected cases.